Synthesis of carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in Alzheimer's disease

Mingzhang Gao, Min Wang, Qi-Huang Zheng

Carbon-11-labeled isonicotinamides

Synthesis of carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in Alzheimer's disease

Mingzhang Gao, Min Wang, Qi-Huang Zheng*

Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, Room 202, Indianapolis, IN 46202, USA

*Corresponding author. Tel.: +1 317-278-4671. Fax: +1 317-278-9711. E-mail address: qzheng@iupui.edu.

This is where the receipt/accepted dates will go; Received Month XX, 2017; Accepted Month XX, 2017 [BMCL RECEIPT]

Abstract—The authentic standards 2-(cyclopropanecarboxamido)-*N*-(4-methoxypyridin-3-yl)isonicotinamide (**4a**) and 2-(cyclopropanecarboxamido)-*N*-(4-(4-methoxyphenyl)pyridin-3-yl)isonicotinamide (**7a**), and their corresponding precursors 2-(cyclopropanecarboxamido)-*N*-(4-hydroxypyridin-3-yl)isonicotinamide (**4b**) and 2-(cyclopropanecarboxamido)-*N*-(4-(4-hydroxyphenyl)pyridin-3-yl)isonicotinamide (**7b**) were synthesized from methyl 2-aminoisonicotinate and cyclopropanecarbonyl chloride with overall chemical yield 47% in three steps, 22% in four steps, 40% in three steps, and 17% in four steps, respectively. The target tracers 2-(cyclopropanecarboxamido)-*N*-(4-[¹¹C]methoxypyridin-3-yl)isonicotinamide ([¹¹C]**4a**) and 2-(cyclopropanecarboxamido)-*N*-(4-(4-[¹¹C]methoxyphenyl)pyridin-3-yl)isonicotinamide ([¹¹C]**7a**) were prepared from the precursors (**4b** and **7b**) with [¹¹C]CH₃OTf through *O*-[¹¹C]methylation and isolated by HPLC combined with SPE in 40-50% radiochemical yield, based on [¹¹C]CO₂ and decay corrected to end of bombardment (EOB). The radiochemical purity was >99%, and the specific activity (SA) at EOB was 370-1110 GBq/μmol with a total synthesis time of ~40-minutes from EOB.

Keywords: Carbon-11-labeled isonicotinamides; Glycogen synthase kinase-3 (GSK-3); Radiosynthesis; Positron emission tomography (PET); Alzheimer's disease (AD).

Alzheimer's disease (AD) is the most common form of dementia and affects over 30 million people worldwide, and there are no reliable disease-modifying therapies at present.¹⁻⁴ Currently, the cause of AD remains unclear and no any effective strategy is approved for preventing, curing and slowing the progress of AD.⁵⁻⁷ To discover more effective treatments, a reliable diagnostic tool is really needed.⁸ Neuroimaging of AD is one of the most active as well as most challenging areas in neuroscience.⁹ Advanced biomedical imaging technique positron emission tomography (PET) is a promising modality for AD, and significant advances have accomplished in this field of molecular imaging.¹⁰ The development of PET imaging probes for *in vivo* detection of Alzheimer's brains is critical for early and accurate diagnosis and for the successful discovery of disease-modifying therapies.¹¹⁻¹³ Currently, aggregated β-amyloid plaques (Aβ) and tau protein are two major

biomarkers for AD.^{14,15} The representative Aβ PET tracers are [¹¹C]PIB¹⁶ and [¹⁸F]Amyvid (formerly known as [¹⁸F]AV-45),¹⁷ as displayed in Figure 1, the representative PET tau tracers include [¹¹C]PBB¹⁸ and [¹⁸F]T807 ([¹⁸F]AV-1451)¹⁹ (Figure 1), and promising clinical PET imaging results with these tracers have been reported.

The success and limitations of Aβ imaging and tau imaging have spurred efforts worldwide to develop new selective PET tracers for different imaging targets, and glycogen synthase kinase-3 (GSK-3) has become a novel and attractive molecular target for treatment and PET imaging of AD.²⁰ The enzyme GSK-3 is a serine/threonine protein kinase, which exists as two isoforms GSK-3α and GSK-3β. GSK-3 plays an important role in a number of diverse cellular processes including metabolism, differentiation, proliferation, and

apoptosis. Thus, GSK-3 is associated with a variety of diseases including AD, type II diabetes, neurological disorders, and cancer.¹ In our previous work, we and other have developed [¹¹C]SB-216763 (GSK-3β/α IC₅₀ (nM) 34.3/34.3, Figure 1) as a PET GSK-3 imaging agent.^{21,22} However, not very high *in vitro* binding affinity (IC₅₀) of SB-216763 and complicated two-step radiosynthesis of [¹¹C]SB-216763 have motivated us to develop the new generation of GSK-3 PET probes. Recently, a new class of isonicotinamides was developed by Bristol-Myers Squibb (BMS) as highly selective, brain penetrable, and orally active GSK-3 inhibitors, and the representative compounds 2-(cyclopropanecarboxamido)-*N*-(4-methoxypyridin-3-yl)isonicotinamide (**4a**) and 2-(cyclopropanecarboxamido)-*N*-(4-(4-methoxyphenyl)pyridin-3-yl)isonicotinamide (**7a**) showed appreciable inhibitory activity with GSK-3β/α IC₅₀ (nM) 3.4/4.5 and 2.1/0.45, respectively.¹ In addition, both compounds **4a** and **7a** possess *O*-methyl position amenable to labeling with carbon-11 for one-step radiosynthesis. Here, we report the synthesis of carbon-11-labeled isonicotinamides (Figure 1) as new potential PET agents for imaging of GSK-3 enzyme in AD.

Figure 1. Chemical structure of [¹¹C]PIB, [¹⁸F]Amyvid ([¹⁸F]AV-45), [¹¹C]PBB3, [¹⁸F]T807 ([¹⁸F]AV-1451), [¹¹C]SB-216763 and carbon-11-labeled isonicotinamides.

The synthesis of isonicotinamides **4a,b** is outlined in Scheme 1, according to the literature method¹ with modifications. Commercial available starting material methyl 2-aminoisonicotinate was reacted with cyclopropanecarbonyl chloride to afford monoacylation intermediate **1** in 88% yield, through changing reaction solvent and controlling amount of acid chloride (1.1-1.2 equivalent), which was different from double acylation in literature.¹ Subsequent treatment with KOH in methanol and water achieved complete conversion to

acylated acid **2**, which upon neutralization with aqueous HCl precipitated out as a white solid in 98% yield. The acid **2** could directly reacted 3-aminopyridines **3a,b** under corresponding amide formation conditions or be firstly converted to the acid chloride with oxalyl chloride then to react with 3-aminopyridines **3a,b**, to give the product isonicotinamides **4a,b** in 55% and 46% yield, respectively.

Scheme 1. Synthesis of isonicotinamides **4a,b**. Reagents, conditions and yields: (i) pyridine, 0 °C; 88%. (ii) KOH, MeOH, RT; 98%. (iii) oxalyl chloride, DMF (cat.), RT; then 3-aminopyridines **3a,b**, DIPEA, RT; 55% and 46%.

The synthesis of isonicotinamides **7a,b** is shown in Scheme 2, according to the literature method²³ with modifications. The acid **2** reacted with 4-iodopyridin-3-amine using same procedure as the synthesis of **4a,b** to obtain an intermediate **5** in 41% yield, which could be converted to the product **7a,b** by Suzuki coupling with aryl boronic acid or ester **6a,b** in 63% and 48% yield, respectively.

Scheme 2. Synthesis of isonicotinamides **7a,b**. Reagents, conditions and yields: (i) oxalyl chloride, DMF (cat.), 0 °C; then 4-iodopyridin-3-amine, DIPEA, 0 °C to RT; 41%. (ii) Na₂CO₃, Pd(PPh₃)₄, dioxane, 110 °C; 63% and 48%.

Synthesis of carbon-11-labeled isonicotinamides [¹¹C]**4a** and [¹¹C]**7a** is presented in Scheme 3. Isonicotinamides desmethyl precursor **4b** or **7b** underwent *O*-[¹¹C]methylation^{24,25} using the reactive [¹¹C]methylating agent [¹¹C]methyl triflate ([¹¹C]CH₃OTf)^{26,27} in acetonitrile at 80 °C under basic conditions (2 N NaOH). The product was isolated by semi-preparative reverse-phase (RP) high performance liquid chromatography (HPLC) with a C-18 column, and then concentrated by solid-phase extraction (SPE)²⁸⁻

³⁰ with a disposable C-18 Light Sep-Pak cartridge to produce the corresponding pure radiolabeled compound [¹¹C]**4a** or [¹¹C]**7a** in 40-50% radiochemical yield, decay corrected to end of bombardment (EOB), based on [¹¹C]CO₂.

Scheme 3. Synthesis of carbon-11-labeled isonicotinamides [¹¹C]**4a** and [¹¹C]**7a**. Reagents, conditions and yields: (i) [¹¹C]CH₃OTf, CH₃CN, 2 N NaOH, 80 °C, 3 min; HPLC-SPE; 40-50%.

The radiosynthesis included three stages: 1) labeling reaction; 2) purification; and 3) formulation. We employed more reactive [¹¹C]CH₃OTf, instead of commonly used [¹¹C]methyl iodide ([¹¹C]CH₃I),³¹ in *O*-[¹¹C]methylation to improve radiochemical yield of [¹¹C]**4a** and [¹¹C]**7a**. We used an Eckert & Ziegler Modular Lab C-11 Methyl Iodide/Triflate module to produce [¹¹C]methylating agent either [¹¹C]CH₃OTf or [¹¹C]CH₃I ([¹¹C]CH₃Br passed through a NaI column). The direct comparison between [¹¹C]CH₃OTf and [¹¹C]CH₃I confirmed this result. The labeling reaction was conducted using a V-vial method. Addition of aqueous NaHCO₃ to quench the radiolabeling reaction and to dilute the radiolabeling mixture prior to the injection onto the semi-preparative HPLC column for purification gave better separation of [¹¹C]**4a** or [¹¹C]**7a** from its pyridinyl hydroxyl precursor **4b** or phenyl hydroxyl precursor **7b**. We used Sep-Pak trap/release method instead of rotatory evaporation for formulation to improve the chemical purity of radiolabeled products [¹¹C]**4a** and [¹¹C]**7a**. In addition, a C18 Light Sep-Pak to replace a C18 Plus Sep-Pak allowed final product formulation with ≤5% ethanol.³² Overall, it took ~40 min for synthesis, purification and dose formulation.

The radiosynthesis was performed in a home-built automated multi-purpose [¹¹C]-radiosynthesis module.³³⁻³⁵ This radiosynthesis module facilitated the overall design of the reaction, purification and reformulation capabilities in a fashion suitable for

adaptation to preparation of human doses. In addition, the module is designed to allow in-process measurement of [¹¹C]-tracer specific activity (SA, GBq/μmol at EOB) using a radiation detector at the outlet of the HPLC-portion of the system. For the reported syntheses, product SA was in a range of 370-1110 GBq/μmol at EOB. The factors that affect the EOB SA significantly to lead to such a wide range from 370 to 1110 GBq/μmol are mainly from two parts: (1) carrier from the [¹¹C]-target, and (2) carrier from the [¹¹C]-radiosynthesis unit.^{36,37} We have optimized the [¹¹C] gas irradiation target system and the [¹¹C]-radiosynthesis unit to eliminate ¹²C carrier-added as much as possible and to reach the high end of the SA. To help produce high SA [¹¹C]CO₂, we usually do 10-minute target pre-burn for 2-3 times, with the same beam current, prior to the actual production run. These pre-burn warm up the cyclotron target and eliminate significant amount of ¹²C carrier in the cyclotron's [¹¹C] gas target. Our Eckert & Ziegler Modular Lab C-11 Methyl Iodide/Triflate module produces [¹¹C]CH₃OTf, convenient gas phase bromination of [¹¹C]methane, and production of [¹¹C]CH₃OTf. This 'dry' method, using Br₂ to generate a [¹¹C]CH₃Br intermediate, differs from other 'dry' method using I₂ and 'wet' method using LiAlH₄ and HI, and seems to help minimize introduction of additional ¹²C carrier after [¹¹C]CO₂ production.²⁷ To further help produce high SA [¹¹C]CH₃OTf, we usually do 2 'test loop' procedures when we set up the module for the actual [¹¹C]CH₃OTf production run and 1 actual [¹¹C]CH₃OTf production run before we do [¹¹C]methylation labeling reaction. These procedures avoid any leak in the module to introduce additional ¹²C carrier and eliminate significant amount of original ¹²C carrier accumulated in the [¹¹C]CH₃OTf production system. Therefore, the SA of our [¹¹C]-tracers is significantly improved. At the end of synthesis (EOS), the SA of [¹¹C]-tracer was determined again by analytical HPLC,³⁸ calculated, decay corrected to EOB, and based on [¹¹C]CO₂, which was in agreement with the 'on line' determined value. In each our [¹¹C]-tracer production, if semi-preparative HPLC was used for purification, then the SA of [¹¹C]-tracer was assessed by both semi-preparative HPLC (during synthesis) and analytical HPLC (EOS); if SPE was used for purification, then the SA of [¹¹C]-tracer was only measured by analytical HPLC at EOS.²⁵

Chemical purity and radiochemical purity were determined by analytical HPLC.³⁸ The chemical purity of the precursors and reference standard was >90%. The radiochemical purity of the target tracer was >99% determined by radio-HPLC through γ-ray (PIN diode) flow detector, and the chemical purity of the target tracer was >90% determined by reversed-phase HPLC through UV flow detector.

The experimental details and characterization data for compounds **1**, **2**, **4a,b**, **5**, and **7a,b** for the tracers [^{11}C]**4a** and [^{11}C]**7a** are given.³⁹

In summary, synthetic routes with moderate to high yields have been developed to produce isonicotinamide precursors and reference standards, and carbon-11-labeled isonicotinamides. The radiosynthesis employed [^{11}C]CH₃OTf for *O*-[^{11}C]methylation at the pyridinyl hydroxyl or phenyl hydroxyl position of the desmethyl precursor, followed by product purification and isolation using a semi-preparative RP HPLC combined with SPE. The carbon-11-labeled isonicotinamides were obtained in high radiochemical yield, radiochemical purity and chemical purity, with a reasonably short overall synthesis time, and high specific activity. This will facilitate studies to evaluate carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in AD.

Acknowledgments

This work was partially supported by Indiana State Department of Health (ISDH) Indiana Spinal Cord & Brain Injury Fund (ISDH EDS-A70-2-079612) in the United States. ^1H NMR and ^{13}C NMR spectra were recorded at 500 and 125 MHz, respectively, on a Bruker Avance II 500 MHz NMR spectrometer in the Department of Chemistry and Chemical Biology at Indiana University Purdue University Indianapolis (IUPUI), which is supported by the United States National Science Foundation (NSF) Major Research Instrumentation Program (MRI) grant CHE-0619254.

References and notes

- Luo, G.; Chen, L.; Burton, C. R.; Xiao, H.; Sivaprakasam, P.; Krause, C. M.; Cao, Y.; Liu, N.; Lippy, J.; Clarke, W. J.; Snow, K.; Raybon, J.; Arora, V.; Pokross, M.; Kish, K.; Lewis, H. A.; Langley, D. R.; Macor, J. E.; and Dubowchik, G. M. *J. Med. Chem.* **2016**, 59, 1041.
- Ariza, M.; Kolb, H. C.; Moechars, D.; Rombouts, F.; Andrés, J. I. *J. Med. Chem.* **2015**, 58, 4365.
- Watanabe, H.; Ono, M.; Saji, H. *ScientificWorldJournal* **2015**, 2015, 124192.
- James, O. G.; Doraiswamy, P. M.; Borges-Neto, S. *Front. Neurol.* **2015**, 6, 38.
- Adlard, P. A.; Tran, B. A.; Finkelstein, D. I.; Desmond, P. M.; Johnston, L. A.; Bush, A. I.; Egan, G. F. *Front. Neurosci.* **2014**, 8, 327.
- Jack, C. R. Jr. *Radiology* **2012**, 263, 344.
- Zimmer, E. R.; Leuzy, A.; Benedet, A. L.; Breitner, J.; Gauthier, S.; Rosa-Neto, P. *J. Neuroinflammation* **2014**, 11, 120.

- Catafau, A. M.; Bullich, S. *Clin. Transl. Imaging* **2015**, 3, 39.
- Villemagne, V. L.; Fodero-Tavoletti, M. T.; Masters, C. L.; Rowe, C. C. *Lancet Neurol.* **2015**, 14, 114.
- Sabri, O.; Seibyl, J.; Rowe, C.; Barthel, H. *Clin. Transl. Imaging* **2015**, 3, 13.
- Wurtman R. *Metabolism* **2015**, 64(3 Suppl 1), S47.
- Zimmer, E. R.; Leuzy, A.; Gauthier, S.; Rosa-Neto, P. *Can. J. Neurol. Sci.* **2014**, 41, 547.
- Ono, M. *Chem. Pharm. Bull.* **2009**, 57, 1029.
- Mach, R. H. *J. Nucl. Med.* **2015**, 55, 1221.
- Shah, M.; Catafau, A. M. *J. Nucl. Med.* **2014**, 54, 871.
- Klunk, W. E.; Engler, H.; Nordberg, A.; Bacskai, B. J.; Wang, Y.; Price, J. C.; Bergström, M.; Hyman, B. T.; Långström, B.; Mathis, C. A. *Neuroimaging Clin. N. Am.* **2003**, 13, 781.
- Carpenter, A. P. Jr.; Pontecorvo, M. J.; Hefti, F. F.; Skovronsky, D. M. *Q. J. Nucl. Med. Mol. Imaging* **2009**, 53, 387.
- Maruyama, M.; Shimada, H.; Suhara, T.; Shinotoh, H.; Ji, B.; Maeda, J.; Zhang, M.-R.; Trojanowski, J. Q.; Lee, V. M.; Ono, M.; Masamoto, K.; Takano, H.; Sahara, N.; Iwata, N.; Okamura, N.; Furumoto, S.; Kudo, Y.; Chang, Q.; Saido, T. C.; Takashima, A.; Lewis, J.; Jang, M. K.; Aoki, I.; Ito, H.; Higuchi, M. *Neuron* **2013**, 79, 1094.
- Chien, D. T.; Bahri, S.; Szardenings, A. K.; Walsh, J. C.; Mu, F.; Su, M. Y.; Shankle, W. R.; Elizarov, A.; Kolb, H. C. *J. Alzheimer's Dis.* **2013**, 34, 457.
- Pandey, M. K.; DeGrado, T. R. *Theranostics* **2016**, 6, 571.
- Wang, M.; Gao, M.; Miller, K. D.; Sledge, G. W.; Hutchins, G. D.; Zheng, Q.-H. *Bioorg. Med. Chem. Lett.* **2011**, 21, 245.
- Li, L.; Shao, X.; Cole, E. L.; Ohnmacht, S. A.; Ferrari, V.; Hong, Y. T.; Williamson, D. J.; Fryer, T. D.; Quesada, C. A.; Sherman, P.; Riss, P. J.; Scott, P. J.; Aigbirhio, F. I. *ACS Med. Chem. Lett.* **2015**, 6, 548.
- Gao, M.; Wang, M.; Zheng, Q.-H. *Bioorg. Med. Chem. Lett.* **2015**, 25, 2953.
- Gao, M.; Wang, M.; Zheng, Q.-H. *Bioorg. Med. Chem. Lett.* **2016**, 26, 1371.
- Gao, M.; Wang, M.; Zheng, Q.-H. *Bioorg. Med. Chem. Lett.* **2016**, 26, 3694.
- Jewett, D. M. *Int. J. Radiat. Appl. Instrum. A* **1992**, 43, 1383.
- Mock, B. H.; Mulholland, G. K.; Vavrek, M. T. *Nucl. Med. Biol.* **1999**, 26, 467.
- Gao, M.; Wang, M.; Mock, B. H.; Glick-Wilson, B. E.; Yoder, K. K.; Hutchins, G. D.; Zheng, Q.-H. *Appl. Radiat. Isot.* **2010**, 68, 1079.
- Wang, M.; Gao, M.; Miller, K. D.; Zheng, Q.-H. *Steroids* **2011**, 76, 1331.
- Wang, M.; Gao, M.; Miller, K. D.; Sledge, G. W.; Zheng, Q.-H. *Bioorg. Med. Chem. Lett.* **2012**, 22, 1569.
- Allard, M.; Fouquet, E.; James, D.; Szlosek-Pinaudm, M. *Curr. Med. Chem.* **2008**, 15, 235.

32. Zheng, Q.-H.; Glick-Wilson, B.; Steele, B.; Shaffer, M.; Corbin, L.; Green, M. *J. Labelled Compd. Radiopharm.* **2015**, *58*, S392.
33. Mock, B. H.; Zheng, Q.-H.; DeGrado, T. R. *J. Labelled Compd. Radiopharm.* **2005**, *48*, S225.
34. Mock, B. H.; Glick-Wilson, B. E.; Zheng, Q.-H.; DeGrado, T. R. *J. Labelled Compd. Radiopharm.* **2005**, *48*, S224.
35. Wang, M.; Gao, M.; Zheng, Q.-H. *Appl. Radiat. Isot.* **2012**, *70*, 965.
36. Gao, M.; Wang, M.; Green, M. A.; Hutchins, G. D.; Zheng, Q.-H. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 1965.
37. Wang, M.; Gao, M.; Xu, Z.; Zheng, Q.-H. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4587.
38. Zheng, Q.-H.; Mock, B. H. *Biomed. Chromatogr.* **2005**, *19*, 671.
39. (a). *General*: All commercial reagents and solvents were purchased from Sigma-Aldrich and Fisher Scientific, and used without further purification. [^{13}C]CH₃OTf was prepared according to a literature procedure.²⁷ Melting points were determined on a MEL-TEMP II capillary tube apparatus and were uncorrected. ^1H and ^{13}C NMR spectra were recorded on a Bruker Avance II 500 MHz NMR Fourier transform spectrometer at 500 and 125 MHz, respectively. Chemical shifts (δ) are reported in parts per million (ppm) relative to an internal standard tetramethylsilane (TMS, δ 0.0) (^1H NMR) and to the solvent signal (^{13}C NMR), and coupling constants (J) are reported in hertz (Hz). Liquid chromatography-mass spectra (LC-MS) analysis was performed on an Agilent system, consisting of an 1100 series HPLC connected to a diode array detector and a 1946D mass spectrometer configured for positive-ion/negative-ion electrospray ionization. The high resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT Classic spectrometer. Chromatographic solvent proportions are indicated as volume: volume ratio. Thin-layer chromatography (TLC) was run using Analtech silica gel GF uniplates ($5 \times 10 \text{ cm}^2$). Plates were visualized under UV light. Preparative TLC was run using Analtech silica gel UV254 plates ($20 \times 20 \text{ cm}^2$). Normal phase flash column chromatography was carried out on EM Science silica gel 60 (230-400 mesh) with a forced flow of the indicated solvent system in the proportions described below. All moisture- and air-sensitive reactions were performed under a positive pressure of nitrogen maintained by a direct line from a nitrogen source. Analytical RP HPLC was performed using a Prodigy (Phenomenex) 5 μm C-18 column, $4.6 \times 250 \text{ mm}$; mobile phase 15% CH₃CN/85% H₂O/0.1% TFA for **4a,b** and 30% CH₃CN/70% 20 mM H₃PO₄ for **7a,b**; flow rate 1.3 mL/min for **4a,b** and 1.0 mL/min for **7a,b**; UV (254 nm) and γ -ray (PIN diode) flow detectors. Semi-preparative RP HPLC was performed using a Prodigy (Phenomenex) 5 μm C-18 column, $10 \times 250 \text{ mm}$; mobile phase 15% CH₃CN/85% H₂O/0.1% TFA for **4a,b** and 30% CH₃CN/70% 20 mM H₃PO₄ for **7a,b**; flow rate 7 mL/min for **4a,b** and 4 mL/min for **7a,b**; UV (254 nm) and γ -ray (PIN diode) flow detectors. C18 Light Sep-Pak cartridges were obtained from Waters Corporation (Milford, MA). Sterile Millex-FG 0.2 μm filter units were obtained from Millipore Corporation (Bedford, MA).
- (b). *Methyl 2-(cyclopropanecarboxamido)isonicotinate (1)*: To a solution of methyl 2-aminoisonicotinate (18.25 g, 120 mmol) in pyridine (200 mL) was added cyclopropanecarbonyl chloride (15.16 g, 145 mmol) at 0 °C. After stirring at 0 °C for 3 h, the reaction mixture was poured into cold 5 N aqueous HCl (500 mL) solution and stirred. The resulting precipitate was filtered, washed with cold water, and dried to give a white solid product **1** (22.08 g). The filtrate was extracted with EtOAc ($3 \times 100 \text{ mL}$), washed with water, brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified by column chromatography on silica gel with eluent (20:80 EtOAc/hexanes) to yield **1** (1.15 g). The two portion of solids were combined to give **1** (23.23 g, 88%). R_f = 0.68 (1:1 EtOAc/hexanes), mp 132-134 °C. ^1H NMR (CDCl₃): δ 0.90-0.95 (m, 2H, CH₂), 1.12-1.15 (m, 2H, CH₂), 1.56-1.61 (m, 1H, CH), 3.93 (s, 3H, OCH₃), 7.58 (d, J = 5.0 Hz, 1H, Ar-H), 8.39 (d, J = 5.0 Hz, 1H, Ar-H), 8.56 (br s, 1H, CONH), 8.73 (s, 1H, Ar-H). MS (ESI): 221 ([M+H]⁺, 100%); MS (ESI): 219 ([M-H]⁻, 1%).
- (c). *2-(Cyclopropanecarboxamido)isonicotinic acid (2)*: KOH (14.52 g, 0.26 mol) was added into the solution of compound **1** (16.2 g, 73.4 mmol) in methanol (200 mL) and water (8 mL). The reaction mixture was stirred at room temperature (RT) for 6 h, then it was evaporated under reduced pressure. The residue was neutralized with 2 N aqueous HCl. The resulting precipitate was filtered, and dried to give a white solid product **2** (14.8 g, 98%). R_f = 0.18 (1:9 MeOH/CH₂Cl₂), mp 277-279 °C. ^1H NMR (DMSO-d₆): δ 0.82-0.83 (m, 4H, $2 \times \text{CH}_2$), 2.00-2.05 (m, 1H, CH), 7.48 (d, J = 5.0 Hz, 1H, Ar-H), 8.45 (d, J = 5.0 Hz, 1H, Ar-H), 8.56 (s, 1H, CONH), 10.99 (1H, OH). MS (ESI): 207 ([M+H]⁺, 100%); MS (ESI): 205 ([M-H]⁻, 15%).
- (d). *2-(Cyclopropanecarboxamido)-N-(4-methoxyppyridin-3-yl)isonicotinamide (4a)*: To a 250 mL flask was added compound **2** (206 mg, 1.0 mmol) in CH₂Cl₂ (20 mL) to give a white suspension. After cooling to 0 °C, oxalyl chloride (0.3 g) and DMF (2 drops) were added. The mixture was stirred at 0 °C for 1 h, then the mixture was evaporated in vacuo. A solution of 4-methoxyppyridin-3-amine (**3a**, 124 mg, 1.0 mmol) in CH₂Cl₂ (5 mL) was added into above mixture at 0 °C, followed by *N,N*-diisopropylethylamine (DIPEA, 260 mg, 2.0 mmol). After stirring at RT for 2 h, the reaction mixture was concentrated under reduced pressure to give a tan oil.

The residue was purified by column chromatography on silica gel with eluent (3:97 MeOH/CH₂Cl₂) to give a white solid product **4a** (164 mg, 55%). R_f = 0.69 (1:9 MeOH/CH₂Cl₂), mp 209-211 °C. ¹H NMR (CDCl₃): δ 0.93-0.97 (m, 2H, CH₂), 1.12-1.15 (m, 2H, CH₂), 1.58-1.63 (m 1H, CH), 3.98 (s, 3H, OCH₃), 6.86 (d, J = 5.5 Hz, 1H, Ar-H), 7.54 (dd, J = 1.0, 5.0 Hz, 1H, Ar-H), 8.30 (s, 1H, Ar-H), 8.35 (d, J = 5.5 Hz, 1H, Ar-H), 8.43 (d, J = 5.0 Hz, 1H, Ar-H), 8.44 (s, 1H, Ar-H), 8.62 (s, 1H, NH), 9.53 (s, 1H, NH). MS (ESI): 313 ([M+H]⁺, 100%); MS (ESI): 311 ([M-H]⁻, 3%).

(e). 2-(Cyclopropanecarboxamido)-N-(4-hydroxypyridin-3-yl)isonicotinamide (**4b**): Compound **4b** was prepared using the same procedure as described for the synthesis of **4a** by substituting 4-hydroxypyridin-3-amine (**3b**) for **3a** as a white solid, yield 46%. R_f = 0.58 (1:9 MeOH/CH₂Cl₂), mp 307-309 °C. ¹H NMR (DMSO-d₆): δ 0.83-0.89 (m, 4H, 2 × CH₂), 2.02-2.08 (m 1H, CH), 6.32 (d, J = 4.5 Hz, 1H, Ar-H), 7.48 (dd, J = 1.5, 6.0 Hz, 1H, Ar-H), 7.73 (d, J = 8.0 Hz, 1H, Ar-H), 8.49 (dd, J = 0.5, 7.0 Hz, 1H, Ar-H), 8.54 (d, J = 1.0 Hz, 1H, Ar-H), 8.76 (s, 1H, Ar-H), 9.43 (s, 1H, NH), 11.04 (s, 1H, NH), 11.68 (s, 1H, OH). ¹³C NMR (DMSO-d₆): δ 8.31, 14.72, 111.18, 113.33, 116.77, 125.50, 128.41, 136.64, 143.37, 149.48, 153.47, 163.43, 170.58, 173.46. MS (ESI): 299 ([M+H]⁺, 70%); MS (ESI): 297 ([M-H]⁻, 17%). HRMS (ESI) calcd for C₁₅H₁₅N₄O₃, 299.1144 ([M+H]⁺); found 299.1137.

(f). 2-(Cyclopropanecarboxamido)-N-(4-iodopyridin-3-yl)isonicotinamide (**5**): Compound **5** was prepared from compound **2** with 4-iodopyridin-3-amine using the same procedure as described for the synthesis of **4a** as a yellow solid, yield 41%. R_f = 0.70 (1:9 MeOH/CH₂Cl₂), mp 156-158 °C. ¹H NMR (DMSO-d₆): δ 0.81-0.85 (m, 4H, 2 × CH₂), 2.02-2.08 (m, 1H, CH), 7.58 (d, J = 5.0 Hz, 1H, Ar-H), 8.07 (d, J = 5.0 Hz, 1H, Ar-H), 8.12 (d, J = 5.0 Hz, 1H, Ar-H), 8.48 (s, 1H, Ar-H), 8.52 (d, J = 5.0 Hz, 1H, Ar-H), 8.60 (s, 1H, Ar-H), 10.55 (s, 1H, NH), 11.01 (s, 1H, NH). MS (ESI): 409 ([M+H]⁺, 100%); MS (ESI): 407 ([M-H]⁻, 100%).

(g). 2-(Cyclopropanecarboxamido)-N-(4-(4-methoxyphenyl)pyridin-3-yl)isonicotinamide (**7a**): To a suspension of compound **5** (82 mg, 0.2 mmol), (4-methoxyphenyl)boronic acid (**6a**, 46 mg, 0.3 mmol), and Na₂CO₃ (53 mg, 0.5 mmol) in dioxane (50 mL) was added tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02 mmol). The reaction mixture was subsequently heated at 110 °C for 15 h. After the reaction was cooled down, it was filtered through Celite, washed with dioxane, and concentrated in vacuo. The resultant residue was purified by column chromatography on silica gel with eluent (2:98 MeOH/CH₂Cl₂) to give a white solid product **7a** (49 mg, 63%). R_f = 0.40 (1:19 MeOH/CH₂Cl₂), mp 170-172 °C. ¹H NMR (CDCl₃): δ 0.91-0.95 (m, 2H, CH₂), 1.09-1.13 (m, 2H, CH₂), 1.55-1.59 (m, 1H, CH), 3.88 (s, 3H, OCH₃), 7.08 (dd, J = 2.0, 7.0 Hz, 2H, Ph-H),

7.23 (d, J = 5.0 Hz, 1H, Ar-H), 7.38 (dd, J = 2.0, 7.0 Hz, 2H, Ph-H), 7.45 (dd, J = 1.5, 5.0 Hz, 1H, Ar-H), 8.16 (s, 1H, Ar-H), 8.37 (d, J = 5.5 Hz, 1H, Ar-H), 8.38 (s, 1H, Ar-H), 8.41 (s, 1H, NH), 8.47 (d, J = 5.0 Hz, 1H, Ar-H), 9.59 (s, 1H, NH); ¹H NMR (DMSO-d₆): δ 0.83-0.88 (m, 4H, 2 × CH₂), 2.05-2.11 (m, 1H, CH), 3.80 (s, 3H, OCH₃), 7.03 (d, J = 7.5 Hz, 2H, Ph-H), 7.43 (d, J = 5.0 Hz, 1H, Ar-H), 7.47 (d, J = 5.0 Hz, 1H, Ar-H), 7.49 (d, J = 7.5 Hz, 2H, Ph-H), 8.48 (s, 2H, Ar-H), 8.55 (d, J = 6.0 Hz, 1H, Ar-H), 8.63 (s, 1H, Ar-H), 10.37 (s, 1H, NH), 11.00 (s, 1H, NH). MS (ESI): 389 ([M+H]⁺, 100%); MS (ESI): 387 ([M-H]⁻, 40%).

(h). 2-(Cyclopropanecarboxamido)-N-(4-(4-hydroxyphenyl)pyridin-3-yl)isonicotinamide (**7b**): Compound **7b** was prepared using the same procedure as described for the synthesis of **7a** by substituting (4-hydroxyphenyl)boronic acid (**6b**) for **6a** as a light blue solid, yield 48%. R_f = 0.35 (1:16 MeOH/CH₂Cl₂), mp 163-165 °C. ¹H NMR (DMSO-d₆): δ 0.80-0.86 (m, 4H, 2 × CH₂), 2.00-2.05 (m, 1H, CH), 6.80 (d, J = 10.5 Hz, 2H, Ph-H), 7.34 (d, J = 10.5 Hz, 2H, Ph-H), 7.40 (s, 1H, Ar-H), 7.41 (s, 1H, Ar-H), 8.44 (d, J = 6.5 Hz, 1H, Ar-H), 8.47 (s, 1H, Ar-H), 9.49 (d, J = 6.5 Hz, 1H, Ar-H), 8.56 (s, 1H, Ar-H), 9.66 (s, 1H, OH), 10.30 (s, 1H, NH), 10.95 (s, 1H, NH). ¹³C NMR (DMSO-d₆): δ 7.73, 14.18, 30.62, 111.54, 115.49, 116.61, 124.11, 126.83, 129.49, 130.68, 143.35, 145.46, 147.86, 148.47, 149.47, 152.74, 157.82, 164.90, 172.73. MS (ESI): 375 ([M+H]⁺, 100%); MS (ESI): 373 ([M-H]⁻, 80%). HRMS (ESI) calcd for C₂₁H₁₉N₄O₃, 375.1457 ([M+H]⁺); found 375.1451.

(i) 2-(cyclopropanecarboxamido)-N-(4-[¹¹C]methoxypyridin-3-yl)isonicotinamide ([¹¹C]**4a**) and 2-(cyclopropanecarboxamido)-N-(4-(4-[¹¹C]methoxyphenyl)pyridin-3-yl)isonicotinamide ([¹¹C]**7a**): [¹¹C]CO₂ was produced by the ¹⁴N(p,α)¹¹C nuclear reaction in the small volume (9.5 cm³) aluminum gas target provided with the Siemens RDS-111 Eclipse cyclotron. The target gas consisted of 1% oxygen in nitrogen purchased as a specialty gas from Praxair, Indianapolis, IN. Typical irradiations used for the development were 58 μA beam current and 15 min on target. The production run produced approximately 25.9 GBq of [¹¹C]CO₂ at EOB. The desmethyl precursor **4b** or **7b** (0.1-0.3 mg) was dissolved in CH₃CN (300 μL). To this solution was added aqueous NaOH (2 N, 2 μL). The mixture was transferred to a small reaction vial. No-carrier-added (high specific activity) [¹¹C]CH₃OTf that was produced by the gas-phase production method²⁷ within 12 min from [¹¹C]CO₂ through [¹¹C]CH₄ and [¹¹C]CH₃Br with silver triflate (AgOTf) column was passed into the reaction vial at RT until radioactivity reached a maximum (2 min), and then the reaction vial was isolated and heated at 80 °C for 3 min. The contents of the reaction vial were diluted with aqueous NaHCO₃ (0.1 M, 1 mL). The reaction vial was connected to a 3-mL HPLC injection loop. The labeled product mixture

solution was injected onto the semi-preparative HPLC column for purification. The product fraction was collected in a recovery vial containing 30 mL water. The diluted tracer solution was then passed through a C-18 Sep-Pak Light cartridge, and washed with water (3×10 mL). The cartridge was eluted with EtOH (3×0.4 mL) to release the labeled product, followed by saline (10-11 mL). The eluted product was then sterile-filtered through a Millex-FG 0.2 μ m membrane into a sterile vial. Total radioactivity was assayed and total volume (10-11 mL) was noted for tracer dose dispensing. The overall synthesis time including HPLC-SPE purification and reformulation was ~40 min from EOB. The same procedure was used to prepare the target tracers [^{11}C]**4a** and [^{11}C]**7a** from their corresponding precursors **4b** and **7b**. Retention times in the analytical HPLC system were: t_{R} **4b** = 4.60 min, t_{R} **4a** = 6.68 min, t_{R} [^{11}C]**4a** = 6.73 min; and t_{R} **7b** = 3.23 min, t_{R} **7a** = 5.02 min, t_{R} [^{11}C]**7a** = 5.12 min. Retention times in the preparative HPLC system were: t_{R} **4b** = 7.70 min, t_{R} **4a** = 10.58 min, t_{R} [^{11}C]**4a** = 10.65 min; and t_{R} **7b** = 4.56 min, t_{R} **7a** = 6.85 min, t_{R} [^{11}C]**7a** = 6.93 min.